FEASIBILITY OF IBREXAFUNGERP FOR THE TREATMENT OF FUNGAL INFECTIONS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
Invasive fungal diseases are a significant cause of morbidity and mortality in haematological patients, particularly those undergoing hematopoietic stem cell transplantation (HSCT) (IFD). Despite the relatively high frequency, diagnosis and treatment remain difficult due to non-specific symptoms and a limited antifungal arsenal.?Despite significantly lower rates of invasive candidiasis (IC), Candida species are becoming more and more resistant to azoles, as well as echinocandins. The FDA recently approved ibrexafungerp, a first-in-class triterpenoid antifungal, for the treatment of vaginal yeast infections. The glucan synthase enzyme in the fungal cell wall is inhibited by this medication.?
The role of ibrexafungerp in haematological patients who acquire fungal infections has not yet been characterised, despite preliminary results from ongoing phase 3 trials in IFD that are being conducted in this area being positive. For adult patients with haematological malignancies who have either had HSCT or received treatment with a novel targeted therapeutic drug, we examine the viability of oral ibrexafungerp-based antifungal therapy in this article. This article outlines four clinical situations where ibrexafungerp, either by itself or in combination with other antifungal medications, was effective in treating resistant fungal infections.?
This article presents four clinical cases where ibrexafungerp, either as a monotherapy or in combination with liposomal amphotericin B, was effective for the treatment of fungal infections when alternative antifungal therapies had previously failed, or had to be avoided due to possible treatment-related toxicities or drug–drug interactions.?